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Background: Among American men, prostate cancer is the most common, non-cutaneous malignancy that
accounted for an estimated 241,000 new cases and 34,000 deaths in 2011. Previous studies have suggested that
Wnt pathway inhibitory genes are silenced by CpG hypermethylation, and other studies have suggested that
genistein can demethylate hypermethylated DNA. Genistein is a soy isoflavone with diverse effects on cellular
proliferation, survival, and gene expression that suggest it could be a potential therapeutic agent for prostate
cancer. We undertook the present study to investigate the effects of genistein on the epigenome of prostate
cancer cells and to discover novel combination approaches of other compounds with genistein that might be of
translational utility. Here, we have investigated the effects of genistein on several prostate cancer cell lines,
including the ARCaP-E/ARCaP-M model of the epithelial to mesenchymal transition (EMT), to analyze effects on
their epigenetic state. In addition, we investigated the effects of combined treatment of genistein with the histone
deacetylase inhibitor vorinostat on survival in prostate cancer cells.
Methods: Using whole genome expression profiling and whole genome methylation profiling, we have
determined the genome-wide differences in genetic and epigenetic responses to genistein in prostate cancer cells
before and after undergoing the EMT. Also, cells were treated with genistein, vorinostat, and combination
treatment, where cell death and cell proliferation was determined.
Results: Contrary to earlier reports, genistein did not have an effect on CpG methylation at 20 μM, but it did affect
histone H3K9 acetylation and induced increased expression of histone acetyltransferase 1 (HAT1). In addition,
genistein also had differential effects on survival and cooperated with the histone deacteylase inhibitor vorinostat
to induce cell death and inhibit proliferation.
Conclusion: Our results suggest that there are a number of pathways that are affected with genistein and
vorinostat treatment such as Wnt, TNF, G2/M DNA damage checkpoint, and androgen signaling pathways. In
addition, genistein cooperates with vorinostat to induce cell death in prostate cancer cell lines with a greater effect
on early stage prostate cancer.
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Among American men, prostate cancer is one of the
most prevalent malignancies, accounting for 241,000
new cases and 34,000 deaths in 2010 [1], underscoring
the importance of exploring new therapeutic approaches,
targets, and the fundamental biological processes of the
progression of this disease. Genistein is the major com-
ponent (50 %) of soy isoflavones found in soybeans with
40 % daidzein and 5–10 % glycitein [2]. Genistein has
been studied extensively and shown to have exciting
antitumor activities including inhibition of tyrosine
kinases, angiogenesis and proliferation [3-6], telomerase
activity [7], oncogene function [8], and non-specific in-
flammation pathways [8,9], as well as induction of apop-
tosis [8,10]. The anticancer activity of genistein in vivo
and in vitro has been demonstrated for carcinomas of
the prostate [5,11-13], oral cavity [14], skin [15], bladder
[6], and vulva [16]. Evidence suggests clearly that genis-
tein has pleitropic effects on cancer cells, but the critical
mechanisms of action remain ill defined.
Recent studies have suggested that gene promoter CpG
methylation can be prevented or reversed by soy isoflavones
[17]. Fang et al. reported that genistein (2–20 μM) inhibited
cell growth, reversed DNA hypermethylation, and reacti-
vated RARβ, p16INK4a, and MGMT in prostate cancer
LNCaP and PC3 cells [17]. Genistein (20–50 μM) also
dose-dependently inhibited DNA methyltransferase activity,
showing substrate- and methyl donor-dependent inhibition.
In addition, other studies have indicated that genistein can
reactivate silenced genes such as the BTG3 tumor suppres-
sor via CpG demethylation and increased H3K9 histone
acetylation [18-20]. These results indicate that genistein
and related soy isoflavones can reactivate epigenetically
silenced genes, suggesting an additional mechanism for
their therapeutic effects in cancer.
Genistein is attractive as a demethylating agent and as
a potential therapeutic agent compared to the nucleoside
analogue 5-aza-2’-deoxycytidine (5-aza) due to its min-
imal toxicity. 5-aza has been shown to have some effect-
iveness in treating various cancer types, but side effects
such as neutropenia and myelosuppression are some-
times observed in patients [21]. Genistein is a naturally
occurring compound that is well tolerated with no
known toxicities [22,23]. Previous studies have shown
that genistein can sensitize prostate cancer cells to treat-
ment with the chemotherapeutic drug docetaxel [8].
Despite many studies regarding genistein, its effects on
demethylation and impacts on gene expression are not
completely understood.
The Wnt and Notch pathways are often deregulated in
prostate cancer and are important in the progression of this
disease. Several negative regulators of the Wnt pathway in-
cluding the adenomatous polyposis coli (APC), secreted
frizzled-related protein (SFRP1), dickkopf-related protein 3(DKK3), and sex determining region Y-box 7 (SOX7) are
hypermethylated in a high proportion of prostate cancers
[24-26]. In addition, another negative regulator of Wnt that
reduces tumor growth, cell migration and invasion, Wnt in-
hibitory factor 1 (WIF1), has also been suggested to be
hypermethylated in prostate cancers [27].
In this study, we tested the hypothesis that demethyla-
tion and induction of Wnt inhibitory genes by treatment
with genistein might result in decreased activity of the
Wnt signaling pathway. We also tested whether genistein
might cooperate with other compounds such as the his-
tone deacetylase (HDAC) inhibitor vorinostat [28] to in-
duce apoptosis. Surprisingly, we found that contrary to
earlier studies, genistein has no effect on CpG methylation
at physiologically relevant concentrations using methyla-
tion specific PCR and whole genome methylation analysis.
Nevertheless, we did observe that genistein affected his-
tone acetylation and cooperates with vorinostat to induce
apoptosis even better than combined treatment of vorino-
stat with 5-aza. Furthermore, whole genome methylation
analysis and whole gene expression analysis of the effects
of genistein, vorinostat, or the combination of both com-
pounds on gene expression in ARCAP-E (epithelial) and
ARCAP-M (mesenchymal) prostate cancer cells provided
insights into the mechanisms of action of genistein in cells
prior to and after undergoing the epithelial-to-mesenchy-
mal transition (EMT) [29].
Methods
Cell lines and prostate patient samples
DU145, PC3, and LNCaP were obtained from the
American Type Culture Collection (Manassas, VA).
DU145, PC3, and LNCaP cells were maintained in T-
media (Gibco) supplemented with 10 % FBS, 200 mM L-
glutamine, and pen-strep antibiotics. ARCaP-E and
ARCaP-M cells were purchased from Novicure
Biotechnology and propagated in MCaP-Medium (Novi-
cure Biotechnology, Inc, Birmingham, AL), supplemen-
ted with 5 % FBS, 200 mM L-glutamine, and pen-strep.
Cells were counted on a hemocytometer after staining
with Trypan Blue. Additionally, prostate patient samples
from primary tumors were obtained under IRB approved
protocols from Emory University Hospital. Clinical char-
acteristics of these samples are provided in Supplemental
Table S1 (Additional file 1: Table S1.)
Materials
Genistein and 5-aza-2’-deoxycytidine (5-aza) were
obtained from Sigma Aldrich (St. Louis, MO), ICG-001
was obtained as a gift from the University of Southern
California in the laboratory of Dr. Michael Kahn, Univer-
sity of Southern California, N-[N-(3,5-Difluorophenace-
tyl)-L-alanyl]-(S)-phenylglcine t-butyl ester (DAPT) was
obtained from Santa Cruz Biotechnology, Inc (Santa
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mide (vorinostat) was obtained from Toronto Research
Chemicals, Inc (North York, ON, Canada). Each drug
was dissolved in dimethylsulfoxide (DMSO) and stored in
aliquots at −20°C.
Methylation specific PCR (MSP)
DNA was extracted using the DNeasy Blood and Tissue Kit
(Qiagen, Valencia, CA). Bisulfite treatment was performed
using the EZ DNA Methylation Direct kit (Zymo Research
Corp, Orange, CA) and MSP was performed using the EZ
DNA Methylation startup kit (Zymo Research Corp, Or-
ange, CA). Methylated and unmethylated primers were
designed and optimized for APC, DKK3 SOX7, WIF1,
SFRP1, and SFRP2 (Additional File 1: Table S2). In addition,
the size of the product and the annealing temperature for
each primer pair are indicated.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as described previously [30]
using 90 % confluent ARCaP-E cells, fixed in 1 % for-
maldehyde and sonicated for 10 minutes. Sonicated
chromatin was immunoprecipitated with H3 acetyl K9
antibody (Abcam, San Francisco, CA,USA) and rabbit
IgG (Vector Laboratories, Burlingame, CA, USA) and
collected with protein G agarose beads (Upstate, Teme-
cula, CA, USA). Cells were washed twice with IP Dilu-
tion Buffer, TSE-500, LiCl Detergent, and TE buffer in
listed order. Beads were then eluted and PCR was per-
formed on the purified DNA using the primers in
Additional File 1: Table S3.
Cell death assay
After indicated drug treatments, cells were trypsinized and
washed twice with 1X PBS. Cells were subsequently resus-
pended in 1X Annexin V binding buffer and incubated with
Annexin V-FITC (Pharmingen Biosciences, San Diego, CA,
USA) for 15 minutes at room temperature. 400 μl of
Annexin binding buffer and 1 μg/mL propidium iodide (PI)
were then added. The total cell death was measured using
the BD FACSCalibur system (BD Biosciences Pharmingen,
San Diego, CA, USA).
Quantitative real time RT-PCR
Total RNA was isolated from cells using the RNeasy
Mini Kit (Qiagen, Valencia, CA). After RNA isolation,
total RNA was reverse transcribed to cDNA and quanti-
tative real-time PCR was performed using the iQ SYBER
Green Supermix on a Bio-Rad iCycler in a 25 μl total
volume reaction. Primer sequences for Real-time RT-
PCR are listed in Additional file 1: Table S4. The relative
gene expression levels were determined by the ΔΔCT
method comparing threshold cycles with β-actin or 18 S
as a normalization control.Bisulfite sequencing
Samples were sequenced on an Ion Torrent Personal Gen-
ome Machine at the Cancer Genomics Shared Resource at
the Winship Cancer Institute. Sample DNAs (600 ng),
which had been previously used for the whole genome
methylation analysis, were bisulfite modified using the EZ
DNA Methylation-Direct kit (Zymo Research) as before.
Methylation-specific primers were designed using Meth-
Primer software [31] to amplify a 175-bp region of the
WIF1 promoter (Forward: AATAGTTTTGGTTGAGG-
GAGTTGTA, Reverse: ACCAACAAACACAAAAAAA-
TACTCC). PCR reaction was performed using 1 μl of
bisulfite-treated DNA templates, 1 X Zymo Taq PreMix
(Zymo Research), and 0.4 μM of each primer in a total
volume of 25 μl. Cycling parameters for PCR were 95°C
5 min, followed by 40 cycles of 95°C 30 s, 58.2°C 30 s, and
72°C 30 s, followed by the extension step at 72°C 10 min,
and 4°C hold. Amplicons were gel-extracted using the
Qiagen Gel Purification kit (Qiagen), and submitted to the
Emory Winship Cancer Institute Cancer Genomics
Shared Resource for Ion Torrent sequencing, which was
performed as described [32]. Sequencing data was ana-
lyzed using PEMapper software (Cutler D, Patel V, Mon-
dal K, Ramachandran D, Steinberg K, Shetty A, Zwick M:
PEMapper: A New Approach to Identifying Genetic
Variation in Second-Generation Sequencing Studies,
submitted).
Whole genome methylation profiling
DNA was isolated from three independent experiments in
which ARCaP-E and ARCaP-M cells were treated with
DMSO control, 20 μM genistein, or 1 μM 5-aza for six
days. Fresh drugs and media were changed every other day.
Additionally, PREC cells (Lonza, Basel, Switzerland) were
used as a normal human prostate cell line control. Total
DNA was submitted to the Emory Winship Cancer Insti-
tute Cancer Genomics Shared Resource for analysis with
Illumina 27 K CpG Methylation Arrays that interrogate
27,578 CpG loci> 14,000 genes using the Illumina Beadsta-
tion 500 instrument. After data normalization, Genome
Studio software (Illumina) was used to compute β values
(range 0–1) defined as β =methylated signal/(methylated +
unmethylated signal). Probes were filtered to include only
those with changes in β values> 0.2, and significance ana-
lysis of microarrays (SAM) software [33] was used to deter-
mine statistically significant changes in methylation. SAM
analysis was completed with two-class unpaired settings,
500 permutations, and FDR <1 %.
Whole genome expression profiling
RNA was isolated from three independent experiments in
which ARCaP-E and ARCaP-M were treated with DMSO
control, 20 μM genistein for 6 days, vorinostat for 48 hrs,
or a combination of vorinostat (48 hrs) plus genistein
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Cancer Institute Cancer Genomics Shared Resource for
processing and hybridization to Illumina Human HT-12 v3
Expression BeadChips that interrogate 48,804 probes. After
hybridization and data normalization, significance analysis
of microarrays (SAM) software was used to determine sig-
nificant differences in gene expression. SAM settings were
two class unpaired, 500 permutations, and a minimum fold
change of 1.5 at FDR <1 %.
Immunoblotting
DMSO and genistein treated cells were collected and cen-
trifuged at 1000 rpm for 5 minutes, and the pellets were
washed twice with 1X PBS. Cells were lysed using lysis buf-
fer. Lysis buffer consisted of 0.137 mol/L NaCl, 0.02 mol/L
TRIS (pH 8.0), 10 % glycerol, 1 % NP40, and a protease in-
hibitor cocktail obtained from Promega (San Luis Obispo,
CA, USA). A mix of cell lysates (50 μg) and laemmli sample
buffer (Bio Rad, Hercules, CA) were made and then heated
at 99°C for 3 minutes. Proteins were separated by SDS-
PAGE electrophoresis and transferred to nitrocellulose for
immunoblotting. After transfer, nitrocellulose membrane
was blocked for 1 hr at room temperature using blocking
buffer from Li-Cor Biosciences (Lincoln, NE, USA). Mem-
brane was incubated with primary antibody Histone acetyl-
transferases 1 (HAT1) (Santa Cruz, Santa Cruz, CA)
overnight at 4°C and then washed three times with 1X PBS
and 0.1 % Tween. To control for equal loading, GAPDH
(Cell Signaling, Danvers, MA) was used as a loading con-
trol. Then the nitrocellulose membrane was incubated with
a secondary fluorescent antibody (LI-COR Biosciences, Lin-
coln, NE, USA). Using the manufacturer’s protocol, mem-
branes were imaged and quantitated using the Odyssey
imaging system (LI-COR Biosciences, Lincoln, NE, USA).
Results
Wnt inhibitory genes are methylated in prostate cancer
patient samples
Tumor suppressor genes are often hypermethylated in
prostate cancer patient tissue samples compared to nor-
mal tissues, and this methylation can correlate with
prognosis [34,35]. To determine if Wnt Inhibitory genes
are methylated in prostate cancer patient samples, we
performed methylation specific PCR (MSP) on eight
prostate cancer patient samples. We observed that
SOX7 was highly methylated, whereas WIF1, SFRP1,
DKK3, and APC were partially methylated in each of
these samples (Figure 1A).
Genistein treatment does not induce demethylation of
wnt-inhibitory genes but does induce expression and
H3K9 acetylation in prostate cancer cells
To test our hypothesis that genistein could demethylate
Wnt inhibitory genes, APC, SOX7, SFRP1, DKK3, andWIF1 were tested for demethylation by MSP in DU145,
PC-3, and ARCaP-E cells following treatment for 6 days
with 20 μM genistein or with 5-aza as a positive control.
Although some studies have used concentrations as high
as 50 μM [20], other previously published studies have
used 20 μM [17], and analysis of genistein concentrations
in the prostates of patients supplemented with 82 mg/day
determined that the median concentration of genistein in
the prostate was only 2.3 μM, suggesting that achieving
50 μM genistein in patients is likely not attainable [23]. 5-
aza treated cells demonstrated significant demethylation
of SOX7 in PC3 and DU145 cells (Additional File 2: Fig-
ure S1), confirming the sensitivity of the MSP assay. Al-
though previous reports indicated that genistein has the
potential to demethylate CpG dinucleotides [17,20], we
observed no demethylation of APC, SOX7, WIF1, or
SFRP1 in DU145, PC3, or ARCaP-E cells when treated
with 20 μM genistein (Figure 1B and Additional File 2:
Figure S1). In addition, we performed whole genome
methylation profiling of ARCaP-E and ARCaP-M cells
treated with DMSO, 1 μM 5-aza, or 20 μM genistein for
6 days. Consistent with the MSP data, we observed no sig-
nificant changes in methylation following genistein treat-
ment across over 14,000 genes tested by this platform
(Figure 1C and Additional File 2: Figure S1). In contrast,
ARCaP-E and ARCaP-M cells treated with 1 μM 5-aza,
exhibited a substantial change in methylation. Further-
more, bisulfite sequencing was performed on 13 CpGs
over 175 basepairs of the WIF1 CpG island to obtain over
1000 reads per genomic DNA sample by next generation
sequencing methods on an Ion Torrent Personal Genome
Machine. Analysis of these 13 CpGs in the WIF1 CpG is-
land in ARCAP-E, ARCAP-M, and PrEC cells indicated
no change in CpG methylation upon genistein treatment
(Figure 1D). Thus, we conclude that treatment with
20 μM genistein for 6 days does not induce CpG demethy-
lation in prostate cancer cells.
It has also been previously reported that genistein can
affect histone acetylation [18,36]. Consequently, we
tested the effect of genistein by ChIP assay and observed
that it did produce substantial changes in H3K9 acetyl-
ation in the promoters of Wnt inhibitory genes. ARCaP-
E cells treated with genistein for 6 days at 20 μM demon-
strated an increase in acetylation in SOX7, APC, DKK3,
WIF1, SFRP1, and SFRP2 (Figure 1E). Additionally, there
was an increase in the histone acetyltransferase 1
(HAT1) protein when treated with genistein (Figure 1F).
To determine if genistein treatment would induce gene
expression of Wnt inhibitory genes, we performed
quantitative real time PCR (QPCR) to determine if there
was an increase in the mRNA levels of SOX7, SFRP2,
SFRP1, APC, and DKK3. We did not observe any signifi-
cant increases in ARCAP-E cells following genistein
treatment, although there was a small but significant
Figure 1 (See legend on next page.)
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Figure 1 Genistein treatment induces hypermethylated Wnt-inhibitory genes via H3K9 acetylation, not CpG demethylation. (A) Wnt
Inhibitory genes are methylated in prostate cancer patient samples. MSP of Wnt inhibitory genes was performed on genomic DNA derived from
paraffin embedded prostate tissues in 8 prostate cancer samples. SOX7 was strongly methylated while WIF1, SFRP1, DKK3, and APC were partially
methylated in multiple patient samples. U = unmethylated, M =methylated. (B) MSP analysis indicates no change in methylation status of APC,
WIF1, SFRP1, SOX7, and DKK3 in DU145, ARCAPE, and PC3 cell lines after treatment with 20 μM genistein for 6 days. (C) Whole genome
methylation profiling using the 27 K CpG Methylation Arrays was performed on ARCAPE and ARCAPM cells treated with DMSO and 20 μM
genistein for 6 days. In addition, 5-aza-deoxy-cytidine was used as a positive control and PREC cells were used as a negative control. No
significant changes in methylation were detected with genistein treatment. Unsupervised hierarchical clustering of 4,190 CpG loci with β-value>
0.5 is shown. (D) Bisulfite sequencing of 175 bp of the WIF1 CpG island across 13 CpG sites indicates high methylation in ARCAP-E and ARCAP-M
cells with or without genistein treatment, and low methylation in PrEC cells. (E) Anti-acetyl histone H3-Lysine9 chromatin immunoprecipitation
(acetyl-H3K9 ChIP) of ARCAP-E cells treated with DMSO control or genistein shows marked increases in acetyl-H3K9 following genistein treatment.
(F) Immunoblot of HAT1 protein shows increased HAT1 protein in ARCaP-E and ARCaP-M after genistein treatment. (G) Gene expression with
genistein treatment in ARCAPE, and ARCAPM cells. Gene expression of indicated Wnt inhibitory genes after treatment with genistein was
determined using QPCR. The data are presented as fold change relative to DMSO control (mean ± SD, triplicate samples from five independent
experiments). Significant p-values (p< 0.05) were computed using the student’s t-test with a two-tailed distribution and are indicated with an
asterisk (*).
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(Figure 1G).
Genistein treatment reduces proliferation and induces
apoptosis in prostate cancer cells alone or in combination
with vorinostat
To determine genistein’s potential as a therapeutic agent
in the treatment of prostate cancer, prostate cancer cell
lines PC3, DU145, ARCaP-E, ARCaP-M and LNCaP
were treated with 20 μM genistein for a total of six days,
1 μM vorinostat for 2 days, and a combination of genis-
tein and vorinostat (Figure 2A). Since genistein treat-
ment increased histone acetylation, we hypothesized that
it might cooperate with histone deacetylase (HDAC)
inhibitors to induce apoptosis. Genistein exhibited only
a minor (5–10 %) effect of increased cell death on these
cells based on Annexin V/PI staining (Figure 2A). There
was an approximate increase of 8 % cell death in DU145
cells, 5 % cell death in ARCaP-E cells, 10 % cell death in
LNCaP cells, and 8 % cell death in PC3 cells when com-
pared to untreated DMSO cohorts. Nevertheless, we
confirmed previous studies [37,38] indicating that genis-
tein was quite effective in inhibiting cell proliferation
(Figure 2B). In addition, there was an increase in cell
death of all prostate models when treated with vorino-
stat and combination genistein and vorinostat with the
largest affect being in the ARCaP-E cell line model.
To compare the effectiveness of genistein and 5-aza,
ARCaP-E and ARCaP-M cells were treated with either
20 μM genistein or 1 μM 5-aza, in combination with the
HDAC inhibitor vorinostat for 48 hrs. Combination treat-
ment of vorinostat and genistein showed that there was a
more than additive effect on cell death in both ARCaP cell
lines (Figure 2C). Also, these data suggest that prostate can-
cer cells that undergo EMT may become less sensitive to
vorinostat treatment. Although 5-aza, as a single agent,
increased cell death more than genistein as a single, when 5-
aza was used in combination with vorinostat, there was nosubstantial increase in cell death. Interestingly, in ARCaP-E
cells, the combined 5-aza and vorinostat actually produced
less cell death than both agents used separately. In addition,
genistein combined with vorinostat was much more effect-
ive than 5-aza combined with vorinostat in inducing cell
death (Figure 2C). This is potentially of significant clinical
relevance because genistein has no known toxicities.
In addition to genistein’s effects on cell death, we also
measured genistein’s effects on cellular proliferation. In
ARCaP-E cells, we observed that genistein was more effect-
ive in inhibiting cell growth than either vorinostat or 5-aza
(Figure 2D). There was greater than 60 % and 50 % inhib-
ition of growth in ARCaP-E and ARCaP-M cell lines, re-
spectively, following genistein treatment. ARCaP-E cells
treated with 5-aza showed only a 35 % reduction in prolif-
eration, whereas ARCaP-M cells had a greater than 50 % in-
hibition of growth with 5-aza alone (Figure 2D).
Importantly, the combination of genistein and vorinostat
decreased proliferation by 80 % in ARCaP-E and greater
than 60 % in ARCaP-M cells. These data show that genistein
is more effective than 5-aza in inhibiting cell proliferation in
ARCAP-E cells, and that combined genistein and vorinostat
has a profound inhibition on cellular proliferation.
DNA damage checkpoint and apoptosis networks
identified by whole genome expression profiling of cells
treated with genistein and vorinostat
To determine the genome-wide effects of genistein, vori-
nostat, and combined treatment on gene expression, we
conducted whole genome expression profiling of ARCaP-
E and ARCaP-M cells using Illumina HT-12 v3 Expression
BeadChips. Genistein treatment had a larger effect on
ARCaP-E cells (291 genes induced and 144 genes
repressed) than on ARCaP-M cells (31 genes induced and
33 repressed). Vorinostat impacted more genes than gen-
istein in both ARCaP-E cells (820 genes induced and 1046
genes repressed) and ARCaP-M cells (1296 genes induced
and 883 genes repressed). As expected, the largest changes
Figure 2 Genistein synergizes with vorinostat to induce apoptosis in prostate cancer cells. (A) Genistein treatment induces apoptosis in
prostate cancer cells. Survival of androgen-independent PC-3 and DU145, androgen-dependent LNCaP, and androgen-repressed ARCaP-E and
ARCaP-M cells in response to genistein, vorinostat, and combination treatment was measured using Annexin V/PI staining. Cells were treated with
20 μM genistein or DMSO for 6 days, 1 μM vorinostat for 2 days, and combination. Apoptosis was quantitated using Annexin V/PI staining. The
data were quantitated showing total cell death. Data are presented as mean ± SE of triplicate experiments. (B) Proliferation of DU145, PC3,
LNCAP, ARCaP-E, and ARCaP-M cells treated with genistein, vorinostat, and combination. Cells were treated with single agents vorinostat (1 μM),
genistein (20 μM), or combination. Mean % proliferation ± SE of triplicate experiments are shown. Growth inhibition was measured using a
hemocytometer following trypan blue staining. (C) Cell death of ARCaP-E and ARCaP-M cell treated with genistein, 5-deoxyazacytidine (5-aza),
and vorinostat. Cells were treated with single agents, 1 μM vorinostat for 48 hrs, or in combination with genistein or 5-aza for 6 days. Total mean
cell death ± SE of triplicate experiments are shown. (D) Cells were treated as in (C) and cell proliferation was assessed. Mean % proliferation ± SE
of triplicate experiments are shown.
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with genistein and vorinostat for ARCaP-E cells (1978
genes induced and 1758 genes repressed) and ARCaP-M
cells (1503 genes induced and 1161 genes repressed)
(Figure 3A). Gene ontology enrichment analysis using the
DAVID knowledgebase [39] and Ingenuity Pathway Ana-
lysis (IPA) [40], demonstrated that the affected genes were
highly enriched in genes involved in DNA damage, cell
cycle arrest, and apoptosis (Tables 1 and 2). Interestingly,
IPA analysis of genes affected by combined genistein and
vorinostat treatment identified a gene network with the
pro-apoptotic Tumor Necrosis Factor alpha (TNFα) as a
major hub (Figure 3B), including the pro-survival gene
BIRC7 (or Livin) which was downregulated 4.8-fold. In
addition, genes involved in the G2/M cell cycle and re-
sponse to DNA damage was also identified (Figure 3C-D).
For example, four members of the minichromosomemaintenance complex (MCM) essential for DNA replica-
tion are strongly upregulated, as are BRCA1, BARD1,
RAD23B, and XRCC2. QPCR analysis following genistein
treatment confirmed reduced levels of BIRC7, as well as
SLUG, HES1, and TGFB1I1 (or ARA55), and several genes
associated with apoptosis (Figure 3E). These data indicate
that genistein affects cell survival and proliferation via
multiple mechanisms including the TNFα-NFκB and
ATM-CHEK2-BRCA1 pathways. Additionally, genes
involved in chromatin modifications and histone acetyla-
tions such as HAT1 were also impacted by genistein treat-
ment (Table 1 and Additional File 3: Figure S2).
Discussion
Genistein is a pleiotropic compound with many clinically
attractive properties. Previous studies have suggested that
some of the mechanisms of action of genistein includes
Figure 3 Whole genome expression profiling of prostate cancer cells treated with genistein, vorinostat, or the combination. (A)
Hierarchical clustering of 1077 probes strongly affected by treatment with genistein and vorinostat. (B) Ingenuity Pathway Analysis (IPA) Network
of genes annotated for function in Apoptosis. Red indicates increased expression after treatment, and green indicates reduced expression. Solid
lines represent direct interactions and dashed lines represent indirect interactions. (C) IPA Network of genes annotated for function in DNA Repair
and Cell Cycle. (D) QPCR data from a subset of genes with functions in apoptosis pathways normalized to ARCAP-E control cells. (E) QPCR
confirmation of down regulation of TGFB1I1/ARA55, SLUG, BIRC7/Livin, and HES1 following genistein treatment. Data are presented as mean ± SE
of triplicate experiments.
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Table 1 Fold changes in ARCAP-E cells (combined vorinostat/genistein vs. DMSO) of critical genes involved in
apoptosis, DNA damage checkpoint, and chromatin structure and remodeling
Symbol Synonym Fold Change Network Symbol Synonym Fold Change Network
GZMB Granzyme B 6.9 Apoptosis CTNNB1 β-catenin 1.7 Apoptosis
TNFRSF6B Decoy Receptor 3 4.8 Apoptosis MTA2 — 1.7 Chromatin
BIRC3 c-IAP2 4.1 Apoptosis CHEK2 RAD53 1.6 DNA Checkpoint
TNF TNFα 3.9 Apoptosis BUB1 — 1.6 DNA Checkpoint
DFFA ICAD 3.8 Apoptosis TGFB1I1 ARA55 −1.8 Apoptosis
BARD1 BRCA1 Associated 3.0 DNA Checkpoint TNFSF10 TRAIL −1.9 Apoptosis
MAD2L1 — 2.4 DNA Checkpoint CREBBP CBP −2.1 Chromatin
HAT1 Histone Acetyltrans-ferase 1 2.4 Chromatin SIRT1 SIR2L1 −2.1 Chromatin
GZMH Granyme H 2.3 Apoptosis ATM TEL1 −2.2 DNA Checkpoint
AURKB Aurora Kinase B 2.2 DNA Checkpoint TNFRSF14 LIGHTR −3.7 Apoptosis
BCL10 — 2.0 Apoptosis BIRC7 Livin −4.8 Apoptosis
BRCA1 — 1.9 DNA Checkpoint
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http://www.biomedcentral.com/1471-2407/12/145inhibition of tyrosine kinases and NFκB, DNA CpG
demethylation, and other mechanisms [3,5,6,18]. Initially,
we hypothesized that genistein would demethylate Wnt
inhibitory genes and induce their expression, possibly
inhibiting the Wnt pathway. Although previous studies
showed that genistein demethylates CpG dinucleotides at
50 μM [20], our experiments showed no effect at 20 μM.
Moreover, analysis of genistein concentrations in the pros-
tates of patients supplemented with 82 mg/day deter-
mined that the median concentration of genistein in the
prostate was only 2.3 μM [23]. Despite the fact that genis-
tein has a low toxicity and is well tolerated at high concen-
trations in individuals, high concentrations of genistein
that are capable of demethylating DNA in a physiological
setting may not be clinically feasible. Nevertheless, genis-
tein may still prove to be useful clinically as a chemopre-
ventative or as a therapeutic agent in combination therapy
with drugs such as vorinostat, since combining genistein
with vorinostat demonstrated a more than additive effect
on inducing cell death (Figure 2A). Genistein was also
tested in combination with a Notch inhibitor (DAPT),
Wnt inhibitor (ICG-001), and an AKT inhibitor (LY-
294002). However, those treatments in combination did
not prove to be as effective in inducing cell death in pros-
tate cancer cells as combination genistein and vorinostat
(Additional File 4: Figure S3).Table 2 Gene ontology analysis of genes affected by combine
knowledgebase (columns 1–4) and ingenuity knowledgebase
GO Term Biological Process Count p-value
GO:0006281 DNA repair 45 1.03E-13
GO:0008219 Cell Death 48 2.73E-03
GO:0022403 Cell Cycle 57 1.63E-14
GO:0006915 Apoptosis 43 1.37E-03
GO:0000075 Cell Cycle Checkpoint 17 1.45E-06
GO:0006325 Chromatin Organization 28 7.01E-03Previous studies have reported that genistein reduces
cell growth and induces apoptosis in a number of cancer
cells [8]. Our data suggest that this may be as a result of
increase in genes that affect the G2/M checkpoint such as
BRCA1, BARD1, BUB1, AURKB, CHEK2, and MAD2L1
as well as genes involved in apoptosis such as GZMB,
DFFA, TNF, BIRC3, BCL10, and BIRC7/Livin (Tables 1
and 2). These data provide evidence for potential mechan-
isms to explain earlier studies showing that genistein sen-
sitizes prostate cells to treatment with docetaxel and
selenium [41,42].
Our data from whole genome expression analysis and
real time PCR validation suggest that the mechanism of
action of cell death from genistein may be due to down
regulation of anti-apoptotic genes such as BIRC7/Livin,
TGFB1I1/ARA55, HES1, and SLUG that are involved in
the TNF-NFκB and the androgen pathway (Figure 3).
SLUG (a.k.a. SNAI2) plays a critical role in mediating
the EMT [43] along with SNAIL [44], the founding
member of this family of transcription factors. HES1 is a
downstream target and mediator of the Notch signaling
pathway [45], suggesting that genistein treatment may
inhibit Notch pathway activity. TGFB1I1/ARA55 is
induced by TGBβ signals and acts as a co-activator for
the androgen receptor [46], suggesting that both TGBβ
signaling and androgen signaling may be inhibited byd genistein and vorinostat treatment using DAVID
(columns 5–7)
IPA Biological Function Count p-value
DNA Replication, Recombination, and Repair 39 7.18E-12
Cell Death 122 1.95E-10
Cell Cycle 105 2.70E-09
Apoptosis 149 1.13E-07
DNA checkpoint control 13 1.90E-06
Binding Of Chromatin 5 1.69E-03
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http://www.biomedcentral.com/1471-2407/12/145genistein. We observed that ARCaP-E cells are more
sensitive to genistein and vorinostat treatment than
ARCaP-M cells (Figure 2C), and we also determined that
there was a greater decrease in BIRC7/Livin, TGFB1I1/
ARA55, HES1, and SLUG in ARCaP-E cells compared
to ARCaP-M cells (Figure 3E), suggesting possible
mechanisms for chemotherapeutic resistance in mesen-
chymal cells compared to epithelial cells.
Conclusion
The effects of genistein treatment on epigenetics and gene
expression are likely due primarily to changes in histone
acetylation rather than CpG methylation. Similar to previ-
ous reports [19,20] we observed an increase of HAT1
upon genistein treatment in our array data (Table 1) and
increase protein levels of HAT1 (Figure 1E). This change
in HAT1 expression may provide a mechanism for
increased H3K9 acetylation and explain why Wnt inhibi-
tory genes such as SOX7 were slightly induced when trea-
ted with genistein despite a lack of change in CpG
methylation. We observed changes in a large number of
genes and pathways that were affected with combinatorial
effects of genistein and vorinostat including the TNF-
NFκB pathway and G2/M cell cycle arrest in response to
DNA damage and repair (Figure 3C and Tables 1 and 2).
In conclusion, we have shown that genistein can co-
operate with vorinostat to induce apoptosis, however, fu-
ture studies are needed to validate this combination in a
clinical setting.
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